已收盘 02-06 16:00:00 美东时间
+0.210
+1.64%
今日重点评级关注:瑞穗:维持Syndax制药"跑赢大市"评级,目标价从410美元升至600美元;HC Wainwright & Co.:维持60 Degrees Pharmaceuticals, Inc."买入"评级,目标价从6美元升至24美元
01-28 10:59
今日重点评级关注:HC Wainwright & Co.:维持Soleno Therapeutics"买入"评级,目标价从110美元升至120美元;富国银行:维持Soleno Therapeutics"超配"评级,目标价从106美元升至114美元
01-21 11:42
JP Morgan analyst Tien-Tsin Huang maintains Remitly Global (NASDAQ:RELY) with a Overweight and lowers the price target from $23 to $22.
01-20 23:19
Financial OutlookRemitly is providing a preliminary outlook for the full year 2026 and medium-term financial targets for 2028.Preliminary 2026 OutlookRevenue: expected to grow in the high teens rangeAdjusted EBITDA:
2025-12-09 22:07
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价;Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Remitly Global shares are trading lower after the company reported Q3 financial...
2025-11-06 06:06
Remitly Global (NASDAQ:RELY) raises FY2025 sales outlook from $1.610 billion-$1.620 billion to $1.619 billion-$1.621 billion vs $1.618 billion estimate.
2025-11-06 05:29
Remitly Global (NASDAQ:RELY) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 60 percent. This is a 300 percent increase over earnings of $0.01 per share from the same
2025-11-06 05:28
今日重点评级关注:花旗:维持Arcus Biosciences"买入"评级,目标价从47美元升至54美元;HC Wainwright & Co.:上调Karyopharm Therapeutics评级至"买入",目标价15美元
2025-10-14 09:56